Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content

References

• Bailey DG, Arnold JMO, Spence JD. (1998). Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101–110.
   PubMed Web of Science ®Google Scholar
• Cancalon PF, Barros SM, Haun C, Widmer WW. (2011). Effect of maturity, processing, and storage on the furanocoumarin composition of grapefruit and grapefruit juice. J Food Sci 76:C543–C548.
   Web of Science ®Google Scholar
• Chen C, Cancalon P, Haun C, Gmitter F. (2011). Characterization of furanocoumarin profile and inheritance toward selection of low furanocoumarin seedless grapefruit cultivars. J Am Soc Hortic Sci 136:358–363.
   Web of Science ®Google Scholar
• De Castro WV, Mertens-Talcott S, Rubner A, Butterweck V, Derendorf H. (2006). Variation of flavonoids and furanocoumarins in grapefruit juices: a potential source of variability in grapefruit juice-drug interaction studies. J Agric Food Chem 54:249–255.
   PubMed Web of Science ®Google Scholar
• Farkas D, Greenblatt DJ. (2008). Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. Expert Opin Drug Metab Toxicol 4:381–393.
   PubMed Web of Science ®Google Scholar
• Fontana E, Dansette PM, Poli SM. (2005). Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413–454.
   PubMed Web of Science ®Google Scholar
• Fukuda K, Ohta T, Oshima Y, Ohashi N, Yoshikawa M, Yamazoe Y. (1997). Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics 7:391–396.
   PubMedGoogle Scholar
• Greenblatt DJ. (2010). Update on drug interactions with grapefruit juice: an evidence-based review. Pharmacy Times 76 (Jan):95–104.
   Google Scholar
• Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL. (2011). Mechanism of cytochrome P450-3A inhibition by ketoconazole. J Pharm Pharmacol 63:214–221.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL. (2010). Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 40:713–720.
   PubMed Web of Science ®Google Scholar
• Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, Yamazoe Y. (2000a). Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 82:122–129.
   PubMedGoogle Scholar
• Guo LQ, Fukuda K, Ohta T, Yamazoe Y. (2000b). Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity. Drug Metab Dispos 28:766–771.
   PubMed Web of Science ®Google Scholar
• Guo LQ, Yamazoe Y. (2004). Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol Sin 25:129–136.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Cancalon P, Widmer WW, Greenblatt DJ. (2011). The effect of grapefruit juice on drug disposition. Expert Opin Drug Metab Toxicol 7:267–286.
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Cerundolo R, Radwanski N, Court MH. (2010). Grapefruit juice, lyophilized grapefruit juice, and powdered whole grapefruit inhibit cytochrome P450-mediated triazolam hydroxylation by beagle dog liver microsomes. J Vet Pharmacol Ther 33:189–195.
   PubMed Web of Science ®Google Scholar
• Mertens-Talcott SU, Zadezensky I, De Castro WV, Derendorf H, Butterweck V. (2006). Grapefruit-drug interactions: can interactions with drugs be avoided? J Clin Pharmacol 46:1390–1416.
   PubMed Web of Science ®Google Scholar
• Obach RS, Walsky RL, Venkatakrishnan K. (2007). Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246–255.
   PubMed Web of Science ®Google Scholar
• Ohta T, Maruyama T, Nagahashi M, Miyamoto Y, Hosoi S, Kiuchi F, Yamazoe Y, Tsukamoto S. (2002). Paradisin C: a new CYP3A4 inhibitor from grapefruit juice. Tetrahedron 58:6631–6635.
   Web of Science ®Google Scholar
• Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB. (2006). A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction. Am J Clin Nutr 83:1097–1105.
   PubMed Web of Science ®Google Scholar
• Paine MF, Widmer WW, Pusek SN, Beavers KL, Criss AB, Snyder J, Watkins PB. (2008). Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine. Am J Clin Nutr 87:863–871.
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. (2000). Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 292:618–628.
   PubMed Web of Science ®Google Scholar
• Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL. (2005). Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 33:764–770.
   PubMed Web of Science ®Google Scholar
• Silverman RB. (1995). Mechanism-based enzyme inactivators. Meth Enzymol 249:240–283.
   PubMed Web of Science ®Google Scholar
• Uesawa Y, Mohri K. (2006a). The use of heat treatment to eliminate drug interactions due to grapefruit juice. Biol Pharm Bull 29:2274–2278.
   PubMed Web of Science ®Google Scholar
• Uesawa Y, Mohri K. (2006b). UV-irradiated grapefruit juice loses pharmacokinetic interaction with nifedipine in rats. Biol Pharm Bull 29:1286–1289.
   PubMed Web of Science ®Google Scholar
• Uesawa Y, Abe M, Fukuda E, Baba M, Okada Y, Mohri K. (2011). Construction of a model to estimate the CYP3A inhibitory effect of grapefruit juice. Pharmazie 66:525–528.
   PubMedGoogle Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. (2000). Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 38:111–180.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. (1996). Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370–379.
   PubMed Web of Science ®Google Scholar
• Widmer W, Haun C. (2005). Variation in furanocoumarin content and new furanocoumarin dimers in commerical grapefruit (Citrus paradisi Macf.) juices. J Food Sci 70:c307–c312.
   Web of Science ®Google Scholar
• Yu J, Buslig BS, Haun C, Cancalon P. (2009). New furanocoumarins detected from grapefruit juice retentate. Nat Prod Res 23:498–506.
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. (2005). Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 44:279–304.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Xue CC, Yu XQ, Li C, Wang G. (2007). Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710.
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A. (2004). Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr Drug Metab 5:415–442.
   PubMed Web of Science ®Google Scholar